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Figure 2. Time dependent kinetics of APE1-catalyzed cleavage activity of various 
oligonucleotide duplexes containing either single İA or İC residue. 10nM of the 3’-[32P]-
labelled (A) İA22•T and (B) İC22•G oligonucleotide duplexes were incubated with 5 nM APE1 
for varying periods of time at 37°C. Lane 1, control, non-treated duplex; lanes 2-4, 6-9 and 11-
15, oligonucleotide duplexes incubated with APE1 for 2 min to 4 h; lane 6, 13 mer size 
marker; lane 11, 14 mer size marker. The arrows and “<” symbol denote the position of the 
23-mer, 13-mer and 14-mer fragments, respectively. (C) 10nM of the 3’-[32P]-labelled 
oligonucleotide duplex was incubated with 10 nM APE1 for varying periods of time at 
37°C. The formation of cleavage product was quantified and plotted against incubation time. 
For details see Materials and Methods. 




Figure 3. Inhibition of AP site cleavage activity of APE1 by İA22•T and İC22•G 
oligonucleotide duplexes. 1nM of 3’-[32P]-labelled THF•G oligonucleotide duplex was 
incubated with 0.5 nM APE1 for 2-20 min at 37°C in the presence or not of increasing 
amounts of nonlabelled 22 mer C•G or İC22•G duplexes under NIR condition. Lane 1, control, 
non-treated THF•G duplex; lane 2, as 1 but APE1 for 2 min; lane 3, as 2 but 5 min; lane 4, as 
2 but 10 min; lane 5, as 2 but 20 min; lane 7, THF•G duplex with APE1 for 5 min; lane 8, as 7 
but 2 nM C•G; lane 9, as 7 but 5 nM C•G; lane 10, as 7 but 10 nM C•G; lane 11, as 7 but 20 
nM C•G; lane 12, as 7 but 40 nM C•G; lane 13, as 7 but 2 nM İC22•G; lane 14, as 7 but 5 nM 
İC22•G; lane 15, as 7 but 10 nM İC22•G; lane 16, as 7 but 20 nM İC22•G; lane 17, as 7 but 
40 nM İC22•G. For details see Materials and Methods. 
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Figure 4. MALDI-TOF MS analysis of the mixture of oligonucleotides arising from the 
incubation of the 22 mer oligonucleotide duplexes containing single İA or İC residue 
with APE1 or DNA glycosylases. Typically, 10 pmol of the lesion containing oligonucleotide 
duplexes were incubated with either 10 nM APE1 under NIR condition at 37°C for 17h or 50 
nM ANPG or 50 nM MUG at 37°C for 30 min and subsequently with 10 nM APE1 at 37°C for 
30 min under "BER+Mg2+" reaction condition. (A) Treatment of İA22•T duplex with APE1; (B) 
Treatment of İC22•G duplex with APE1; (C) Treatment of İA22•T duplex with ANPG and 
APE1; (D) Treatment of İC22•G duplex with MUG and APE1. Peaks corresponding to 
complementary strands are indicated in grey. For details see Materials and Methods. 
 - 4 -
 
 
Figure 5. In vitro reconstitution of the long-patch NIR pathway using oligonucleotide 
duplex containing single İA residue. 10 nM of non-labelled 40 mer İA-PP•T oligonucleotide 
duplex was incubated for 3 h at 37°C in the presence of 10 nM APE1, 2 nM FEN1, 0.02 U 
POLȕ and 20 U T4 DNA ligase in the reaction buffer containing 50 mM HEPES-KOH (pH 7.2), 
30 mM NaCl, 3 mM MgCl2, 2 mM ATP, 0.1 mg/ml BSA, 2 mM DTT, 5 mCi of [Į-32P]dATP and 
50 ȝM each of dGTP, dCTP and TTP. Lane 1, 20 mer size marker; lane 2, İA-PP•T incubated 
with all proteins except APE1; lane 3, except FEN1; lane 4, except POLȕ; lane 5, except 
ligase; lane 6, in the presence of all proteins; lane 7, 40 mer size marker.  
(B) Kinetics of the full length product formation in in vitro reconstitution of the long-patch NIR 
pathway for ĮdA PN•T and İA-PP•T and of the short-patch BER pathway for İA-PP•T. For 
details see Materials and Methods. 
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Figure 6. DNA repair activities towards ĮdA•T, İA22•T and İC22•G oligonucleotide 
duplexes in HeLa cells extracts. (A)10nM of 3’-[32P]-labelled ĮdA•T, İA22•T and İC22•G 
oligonucleotide duplexes were incubated for 1 h at 37°C in the presence of 0.5 ȝg of cell-free 
extracts from siRNA-treated HeLa cells under either "BER+EDTA" or "NIR+ZnCl2" condition. 
Cell-free extracts were prepared from HeLa cells treated either with 100 nM of non-specific 
siRNA (siControl), or with 100 nM of APE1-specific siRNA (siAPE1). Lane 1, control, non-
treated ĮdA•T duplex; lane 2, as 1 but probed with control extract under BER+EDTA 
condition; lane 3, as 2 but under NIR+ZnCl2 condition; lane 4, as 1 but probed with APE1-
silenced extract under NIR+ZnCl2 condition; Lane 5, control, non-treated İA22•T duplex; lane 
6, as 5 but probed with control extract under BER+EDTA condition; lane 7, as 6 but under 
NIR+ZnCl2 condition; lane 8, as 5 but probed with APE1-silenced extract under NIR+ZnCl2 
condition; Lane 9, control, non-treated İA22•T duplex; lane 10, as 9 but probed with control 
extract under BER+EDTA condition; lane 11, as 10 but under NIR+ZnCl2 condition; lane 12, 
as 9 but probed with APE1-silenced extract under NIR+ZnCl2 condition.  
(B)10nM of 3’-[32P]-labelled İA22•T oligonucleotide duplexes were incubated for 3 h at 37°C 
in the presence of 5 ȝg of cell-free. Lane 1, control, non-treated İA22•T duplex; lane 2, 14 
mer size marker, lane 3, as 1 but probed with control extract under NIR+ZnCl2 condition; lane 
4, 14 mer size marker; lane 5, as 1 but probed with control extract under BER+EDTA 
condition; lane 6 as 1 but probed with APE1-silenced extract under NIR+ZnCl2. For details see 
Materials and Methods. 




Figure 7. APE1-catalyzed NIR activity towards oligonucleotide duplexes containing 
single Tg residue. 10nM of 3’-[32P]-labelled 30 mer Tg-RT•A and 19 mer Tg19•A 
oligonucleotide duplexes were incubated for 30 min or 2 h at 37°C in the presence of 20 nM 
Fpg or 10 nM APE1 under BER+EDTA or NIR condition. (A) Tg-RT•A and (B) Tg19•A 
duplexes. Lane 1, control nontreated Tg-RT•A duplex; lane 2 as 1 but treated with Fpg under 
BER condition for 30 min at 37°C; lane 3, as 1 but treated with APE1 under BER condition; 
lane 4, as 3 but under NIR condition; lane 5, control non-treated Tg19•A duplex; lane 6 as 5 
but treated with Fpg under BER condition for 30 min at 37°C; lane 7, as 5 but treated with 
APE1 under BER condition; lane 8, as 7 but under NIR condition. For details see Materials 
and Methods. 




Supporting Information Figure S1. Dependence of APE1-catalyzed NIR activity on 
reaction conditions. 10nM of 3’-[32P]-labelled oligonucleotide duplex containing a single İ-
base was incubated for 1-2 h at 37°C with 5 nM APE1 under NIR and BER conditions, unless 
otherwise stated. (A) İC22•G and (B) İA22•T duplexes. Lanes 1 and 9, control, non-treated 
duplex; lanes 2 and 10, duplex incubated with 20 nM MUG and ANPG for 20 min and then 
with 10 nM APE1 for 20 min under "BER+Mg2+" reaction condition; lanes 3 and 11, 13 mer 
size marker; lanes 4 and 12, 14 mer size marker; lanes 5 and 13, duplexes incubated with 
APE1 for 1 h under NIR condition; lanes 6 and 14, duplexes incubated with APE1 for 1 h 
under BER condition; lanes 7 and 15, duplexes incubated with APE1 for 2 h under NIR 
condition; lanes 8 and 16, duplexes incubated with APE1 for 2 h under BER condition. For 
details see Materials and Methods. 
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Supporting Information Figure S2A. Action of various NIR AP endonucleases towards oligonucleotide duplex 
containing a single İ-base. 10nM of 22 mer 3’-[32P]-labelled İA22•T and İC22•G oligonucleotide duplexes were incubated 
with either 10 nM Nfo, or 10 nM Apn1 or 10 nM APE1 for 30 min or 2 h at 37°C, unless otherwise stated. Lane 1, control, 
non-treated İA22•T; lane 2, as 1 but 20 nM ANPG and 10 nM APE1 under BER+Mg2+ condition; lane 3, 13 mer size 
marker; lane 4, as 1 but Nfo for 30 min; lane 5, as 4 but 2 h; lane 6, as 1 but Apn1 for 30 min; lane 7, as 6 but 2 h; lane 8, as 
1 but APE1 for 30 min; lane 9, 14 mer size marker; lane 10, as 8 but 2 h; lane 11, control, non-treated İC22•G; lane 12, as 1 
but 20 nM MUG and 10 nM APE1 under BER+Mg2+ condition; lane 13, as 11 but Nfo for 30 min; lane 14, as 13 but 2 h; 
lane 15, as 11 but Apn1 for 30 min; lane 16, as 15 but 2 h; lane 17, as 11 but APE1 for 30 min; lane 18, as 17 but 2 h. For 
details see Materials and Methods.  
 
Supporting Information Figure S2B. Action of various NIR AP endonucleases towards oligonucleotide duplex 
containing a single İ-base. 10nM of 22 mer 3’-[32P]-labelled ĮdA-RT•T, Tg RT•A, İA22•T and İC22•G oligonucleotide 
duplexes were incubated with either 1 nM or 5 nM Nfo, or 1 nM or 5 nM Apn1 for 30 min or 2 h at 37°C under NIR 
condition. Lane 1, control, non-treated ĮdA-RT•T; lane 2, as 1 but 1 nM Nfo for 30 min; lane 3, as 1 but 1 nM Apn1 for 30 
min, lane 4, control, non-treated Tg RT•A; lane 5, as 4 but 20 nM Fpg under BER+Mg2+ condition; lane 6, as 4 but 1 nM 
Nfo for 2h, lane 7, as 4 but 5 nM Nfo for 2h; lane 8, as 4 but 1 nM Apn1 for 2h; lane 9, as 4 but 5 nM Apn1 for 2h, line 10, 
control, non-treated İA22•T; lane 11, 13 mer size marker; lane 12, as 10 but 1 nM Nfo for 2h; lane 13, as 10 but 1 nM Apn1 
for 2h, lane 14, 14 mer size marker, line 15, control, non-treated İC22•T; line 16, as 15 but 1 nM Nfo for 2h; lane 17, as 15 
but 1 nM Apn1 for 2h. For details see Materials and Methods. 
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Supporting Information Figure S3. Comparison of NIR and AP endonuclease activities 
of APE1-WT and mutant APE1-D308A proteins. 10nM of 22 mer 3’-[32P]-labelled İA-
DL10•T, THF•T and ĮdA•T oligonucleotide duplexes were incubated with varying amounts of 
the APE1 proteins under NIR condition, and products of the reaction were analyzed using 
denaturing PAGE. (A) İA-DL10•T duplex was incubated with varying amounts of the APE1-
WT and APE1-D308A mutant proteins for 4 h at 37°C. Lane 1, control, non-treated İA-
DL10•T; lane 2, 20 nM ANPG and 10 nM APE1 under BER+Mg2+ condition; lane 3, 5 nM of 
APE1-WT; lane 4, 25 nM of APE1-WT; lane 5, 100 nM of APE1-WT; lane 6, 5 nM of APE1-
D308A; lane 7, 25 nM of APE1- D308A; lane 8, 100 nM of APE1- D308A. (B) THF•T and 
ĮdA•T duplexes were incubated with varying amounts of the APE1-WT and APE1-D308A 
mutant proteins for 5 min at 37°C. Lane 1, control, non-treated THF•T; lane 2, 0.02 nM of 
APE1-WT; lane 3, 0.1 nM of APE1-WT; lane 4, 0.5 nM of APE1-WT; lane 5, 0.02 nM of 
APE1-D308A; lane 6, 0.1 nM of APE1- D308A; lane 7, 0.5 nM of APE1-D308A; Lane 8, 
control, non-treated ĮdA•T; lane 9, 0.1 nM of APE1-WT; lane 10, 0.5 nM of APE1-WT; lane 
11, 2.5 nM of APE1-WT; lane 12, 0.1 nM of APE1-D308A; lane 13, 0.5 nM of APE1- D308A; 
lane 14, 2.5 nM of APE1- D308A. For details see Materials and Methods.  
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Supporting Information Figure S4. Electrophoretic Mobility Shift Assay (EMSA) of APE1 
endonuclease with oligonucleotide duplexes containing a single İ-base.The standard 
binding reaction mixture (20 ȝl) contained 20 mM Hepes-KOH, pH 7.6, 50 mM KCl, 10 
ȝM or 100 ȝM MgCl2, 10 nM of 22 mer 3’-[32P]-labelled İA22•T, İC22•G, A22•T and C22•G 
and 250 nM or 500 nM APE1. The mixture was incubated for 10 min on ice, after which an 
aliquot was analyzed by electrophoresis on a 8% non-denaturing polyacrylamide gel (19:1 
acrylamide/bisacrylamide) at 160 V for 14 h at +4 °C. Lane 1, control, İA22•T in 10 ȝM MgCl2 
buffer without APE1, lane 2, as 1 but 250 nM APE1; lane 3, as 1 but 500 nM APE1; lane 4, 
control, İA22•T in 100 ȝM MgCl2 buffer without APE1, lane 5, as 4 but 250 nM APE1; lane 6, 
as 4 but 500 nM APE1; lane 7, control, A22•T in 100 ȝM MgCl2 buffer without APE1, lane 8, 
as 7 but 500 nM APE1; lane 9, control, İC22•T in 10 ȝM MgCl2 buffer without APE1, lane 10, 
as 9 but 250 nM APE1; lane 11, as 9 but 500 nM APE1; lane 12, control, İC22•T in 100 ȝM 
MgCl2 buffer without APE1, lane 13, as 12 but 250 nM APE1; lane 14. as 12 but 500 nM 
APE1; lane 15, control, C22•G in 100 ȝM MgCl2 buffer without APE1, lane 16, as 15 but 500 
nM APE1. For details see Materials and Methods. 
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Supporting Information Figure S5. Time kinetics of in vitro reconstitution of the long-
patch NIR pathway and of the short-patch BER pathway using oligonucleotide duplex 
containing single ĮdA or İA residue. 10 nM of non-labelled (A) 34 mer ĮdA-PN•T and (B) 
40 mer İA-PP•T oligonucleotide duplex was incubated for varied time ranging from 0.5 to 120 
min at 37°C in the presence of 10 nM APE1, 2 nM FEN1, 0.01 U POLȕ and 4 U T4 DNA 
ligase in the reaction buffer containing 50 mM HEPES-KOH (pH 7.2), 30 mM NaCl, 3 mM 
MgCl2, 2 mM ATP, 0.1 mg/ml BSA, 2 mM DTT, 5 mCi of [Į-32P]dATP and 50 ȝM each of 
dGTP, dCTP and TTP. (A)Lane 1, 34 mer size marker; lane 2, product formation after 0 min, 
lane 3, after 10 min; lane 4, after 30 min; lane 5, after 60 min, lane 6, after 120 min; (B) Lane 
1, product formation after 0 min, lane 2, after 10 min; lane 3, after 30 min; lane 4, after 60 min, 
lane 5, after 120 min; lane 6, 20 mer size marker; lane 7, 40 mer size marker. (C) 10 nM of 
non-labelled 40 mer İA-PP•T oligonucleotide duplex was incubated for varied time ranging 
from 0.5 to 120 min at 37°C in the presence of 40 nM ANPG, 5 nM APE1, 2 nM FEN1, 0.01 U 
POLȕ and 4 U T4 DNA ligase in the reaction buffer containing 20 mM HEPES-KOH (pH 7.6), 
50 mM KCl, 5 mM MgCl2, 2 mM ATP, 0.1 mg/ml BSA, 1 mM DTT and 5 mCi of [Į-32P]dATP. 
Lane 1, 40 mer size marker; lane 2, product formation after 0.5 min, lane 3, after 10 min; lane 
4, after 30 min; lane 5, after 60 min, lane 6, after 120 min; lane 7, 20 mer size marker. For 
details see Materials and Methods. 




Supporting Information Figure S6. In vitro reconstitution of the long-patch NIR pathway 
using oligonucleotide duplex containing single ĮdA residue. 10 nM of non-labelled 34 
mer ĮA-PN•T oligonucleotide duplex was incubated for 3 h at 37°C in the presence of 10 nM 
APE1, 2 nM FEN1, 0.02 U POLȕ and 20 U T4 DNA ligase in the reaction buffer containing 50 
mM HEPES-KOH (pH 7.2), 30 mM NaCl, 3 mM MgCl2, 2 mM ATP, 0.1 mg/ml BSA, 2 mM 
DTT, 5 mCi of [Į-32P]dATP and 50 ȝM each of dGTP, dCTP and TTP. Lane 1, ĮA-PN•T 
incubated with all proteins except APE1; lane 2, except FEN1; lane 3, except POLȕ; lane 4, 
except ligase; lane 5, in the presence of all proteins. The arrows denote the position of the 16 
mer cleavage product and 34 mer full-length product. For details see Materials and Methods.  
 
 
 
 
